Sustained.

The survival benefit at 4 years with nivolumab over docetaxel in patients with advanced non-small cell lung cancer. Among the relatively small group of patients with sustained response at 6 months, their 4 year overall survival rate was a whopping 56%. | Antonia, Lancet Oncol 2019

Comments

  1. You’ve made some decent points there. I looked on the internet for more information about the issue and found most people will go along with your views on this website.

    jogos friv 4 school
    friv Games school
    a10games


    ReplyDelete

Post a Comment

Popular Posts